• Pre Clinical And Clinical Research

GMP plasmids released – Ready to start GMP production of CG01

The plasmids have been released at Cobra Biologics and are ready to be used as starting material for the GMP batch that will be used in the first clinical study scheduled to begin in 2022.

Applications invited for Accelerate@Babraham life science start-up competition

Five months, five companies: Life-changing ideas, game-changing support. Accelerate@Babraham, the bio-entrepreneurial incubator initiative founded and developed by the Babraham Research Campus - supported by key industry and investor organisations - opens applications for its 2021/22 cohort today.

New data from AKL Research and Development advances understanding of its investigational osteoarthritis drug APPA to protect against joint damage

AKL Research and Development (AKLRD), a UK pharmaceutical company which develops novel solutions for inflammatory diseases with a high unmet need, unveils new data at the Osteoarthritis Research Society International (OARSI) Virtual World Congress (April 29 – May 1) indicating its investigational oral osteoarthritis (OA) drug APPA can modulate cellular function, reduce inflammation and inhibit bone resorption associated with joint degradation caused by the disease.

WCCT GLOBAL (an Altasciences Company) Clinic Expansion

Laval, Quebec, March 23, 2021 – WCCT Global, an Altasciences company, announced the expansion of their clinical pharmacology unit and laboratory earlier this year. Today, Altasciences confirms the unit dosed its first study participants.

Medannex unveils the multiple anti-cancer effects of MDX-124 at AACR Annual Meeting 2021

Medannex Ltd (Edinburgh) today announced the presentation of new data at the annual meeting of the American Association for Cancer Research (AACR), highlighting the multi-faceted anti-cancer activity of MDX-124 - the company’s proprietary therapeutic antibody.

FairJourney Biologics enters next-generation antibody discovery collaboration with argenx

• Collaboration to leverage IONTAS proprietary mammalian display technology • Differentiated antibody candidates that emerge from collaboration may advance into argenx immunology pipeline

Guest Blog|Could our immune system be why COVID-19 is so deadly?

Respiratory viruses such as SARS-CoV-2 often catalyse an overactive immune response that leads to a life-threatening cycle, known as a cytokine storm. Analysing cytokine responses from patients has unearthed glaringly important differences in how SARS-CoV-2 affects cytokines compared to other common respiratory viruses.

Medannex sweeps the board at Scotland’s Life Sciences Annual Awards

Medannex Ltd (Edinburgh) this week received multiple awards in recognition of notable successes in several key areas. The late-stage biopharmaceutical company, developing novel treatments for cancers and autoimmune diseases, was declared the winner in all three categories in which it was nominated at Scotland’s Life Sciences Annual Awards.

IONTAS identifies novel SARS-CoV-2 neutralising antibodies

• Potent antibodies shown to retain binding to major COVID-19-causing “South African” variant • IONTAS now seeking development partners

Altasciences Doubles Square Footage of Their CDMO Facility

Altasciences Doubles Square Footage of Their CDMO Facility